Danaher Corp (DHR)

$192.94 +2.47 (1.30%)
Market Cap 136.39B
Revenue (ttm) 23.88B
Net Income (ttm) 3.90B
EPS (ttm) N/A
PE Ratio 25.04
Forward PE 24.26
Profit Margin 16.33%
Debt to Equity Ratio 0.32
Volume 4,419,700
Avg Vol 3,904,688
Day's Range N/A - N/A
Shares Out 716.05M
Stochastic %K 35%
Beta 0.75
Analysts Strong Sell
Price Target $242.90

Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment offers bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell cu...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 202 828 0850
Fax: 202 828 0860
Address:
2200 Pennsylvania Avenue N.W., Suite 800W, Washington, United States
BillionerOfKing
BillionerOfKing Sep. 18 at 4:01 AM
$DHR Current Stock Price: $192.89 Contracts to trade: $190 DHR Sep 19 2025 Call Entry: $3.40 Exit: $4.67 ROI: 37% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 17 at 6:05 PM
Enter: $DHR OCT 10 2025 $195 CALLS Buy in Price: $3.98 - $5.00 Take Profit: $5.77 Stop Bleeding: $3.50 ROI Potential: 45% Exit Within: 201 Minutes https://moneygroup.us/alerts
0 · Reply
ZacksResearch
ZacksResearch Sep. 16 at 4:36 PM
$DHR struggles as Life Sciences segment faces headwinds 📉 Core revenues from DHR's Life Sciences segment declined 4% YoY in Q1 and fell 2.5% YoY in Q2, hurt by weak demand in academic and government markets. However, increased demand in microelectronics and aerospace end markets and new products like ZenoTOF 8600 are supporting growth. Meanwhile, shares are down 30.8% over the past year, with a high P/E ratio of 22.62X vs. the industry's 15.09X. See the full analysis here 👉 https://www.zacks.com/stock/news/2752326/danahers-life-sciences-segment-shrinks-whats-the-path-forward?cid=sm-stocktwits-2-2752326-body-12649&ADID=SYND_STOCKTWITS_TWEET_2_2752326_BODY_12649
0 · Reply
ZacksResearch
ZacksResearch Sep. 16 at 3:36 PM
$DHR Life Sciences is shrinking — what’s next? 🧬 Revenues are sliding on weak demand, but fresh products and biotech advances could open new growth paths. Full outlook here 👉 https://www.zacks.com/stock/news/2752326/danahers-life-sciences-segment-shrinks-whats-the-path-forward?cid=sm-stocktwits-2-2752326-teaser-12647&ADID=SYND_STOCKTWITS_TWEET_2_2752326_TEASER_12647
0 · Reply
HODLcoin
HODLcoin Sep. 16 at 2:17 PM
$DHR so bullish 🚀
0 · Reply
WSAnalysis
WSAnalysis Sep. 15 at 4:30 PM
$DHR this has to be one of the Best Buy’s in the market for upside. $ONTO isn’t far off. Sold $TSLA. Repositioning
0 · Reply
SilverEagle
SilverEagle Sep. 15 at 4:28 PM
$DHR gonna slip down to pre covid highs?
1 · Reply
StockAutoPro
StockAutoPro Sep. 15 at 2:08 PM
$DHR: Buy target $188.05 Sell target $199.55 Consider buying as recent acquisitions in life sciences sector could boost growth.
0 · Reply
StockAutoPro
StockAutoPro Sep. 14 at 3:09 PM
$DHR: Buy target $188.05 Sell target $199.55 Despite pandemic-related challenges, this DHR sector company shows strong growth potential due to its innovative product line.
0 · Reply
WSAnalysis
WSAnalysis Sep. 13 at 12:44 AM
$DHR time to buy
1 · Reply
Latest News on DHR
Rosen Law Firm Investigates Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation – DHR

Sep 17, 2025, 12:42 PM EDT - 12 hours ago

Rosen Law Firm Investigates Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation – DHR

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation - DHR

Sep 15, 2025, 6:05 PM EDT - 2 days ago

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation - DHR

Analysts' Top S&P 500 Stocks to Buy Now

Sep 11, 2025, 2:26 PM EDT - 6 days ago

Analysts' Top S&P 500 Stocks to Buy Now

HWM SPGI

Beckman Coulter Diagnostics Launches Industry First Fully Automated, High Throughput BD-Tau Research Use Only Immunoassay Test, Advancing Neurodegenerative Clinical Research

Sep 10, 2025, 8:31 AM EDT - 7 days ago

Beckman Coulter Diagnostics Launches Industry First Fully Automated, High Throughput BD-Tau Research Use Only Immunoassay Test, Advancing Neurodegenerative Clinical Research

Danaher Announces Quarterly Dividend

Sep 9, 2025, 4:15 PM EDT - 8 days ago

Danaher Announces Quarterly Dividend

DHR Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation - DHR

Sep 5, 2025, 8:39 PM EDT - 12 days ago

DHR Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation - DHR

mRNA Biotechs - Long-Term Value Risks Abound

Aug 28, 2025, 6:20 AM EDT - 20 days ago

mRNA Biotechs - Long-Term Value Risks Abound

ALNY BNTX GRAL ILMN IONS MRNA RGEN

Danaher Stock Closes Near Day's High After Key Trading Signal

Aug 4, 2025, 7:13 AM EDT - 6 weeks ago

Danaher Stock Closes Near Day's High After Key Trading Signal

Danaher Appoints Jonathan Leiken as General Counsel

Jul 31, 2025, 4:15 PM EDT - 6 weeks ago

Danaher Appoints Jonathan Leiken as General Counsel

Investors decided the good outweighs the bad with Danaher, says Jim Cramer

Jul 24, 2025, 8:08 PM EDT - 7 weeks ago

Investors decided the good outweighs the bad with Danaher, says Jim Cramer

Danaher Q2 2025 Update

Jul 24, 2025, 3:30 PM EDT - 7 weeks ago

Danaher Q2 2025 Update

Danaher Stock: Attractively Valued And Poised For Growth Acceleration

Jul 23, 2025, 9:50 AM EDT - 2 months ago

Danaher Stock: Attractively Valued And Poised For Growth Acceleration

Danaher Corporation (DHR) Q2 2025 Earnings Call Transcript

Jul 22, 2025, 1:18 PM EDT - 2 months ago

Danaher Corporation (DHR) Q2 2025 Earnings Call Transcript

Cramer's Stop Trading: Danaher

Jul 22, 2025, 10:33 AM EDT - 2 months ago

Cramer's Stop Trading: Danaher

Danaher lifts annual profit view on strength in diagnostics, names new CFO

Jul 22, 2025, 7:51 AM EDT - 2 months ago

Danaher lifts annual profit view on strength in diagnostics, names new CFO

Danaher Announces Transition Plan for Chief Financial Officer

Jul 22, 2025, 6:02 AM EDT - 2 months ago

Danaher Announces Transition Plan for Chief Financial Officer

Danaher Reports Second Quarter 2025 Results

Jul 22, 2025, 6:00 AM EDT - 2 months ago

Danaher Reports Second Quarter 2025 Results

45 Barron's 2025 Mid-Year Pro-Picks: 3 Ideal July DiviDogs

Jul 17, 2025, 9:14 AM EDT - 2 months ago

45 Barron's 2025 Mid-Year Pro-Picks: 3 Ideal July DiviDogs

AEP AGNC ALL FAF FLMI GDEN JAAA

Danaher: Biotech Momentum, Cost Cuts And Valuation Re-Rating Should Drive Upside

Jun 30, 2025, 4:23 AM EDT - 2 months ago

Danaher: Biotech Momentum, Cost Cuts And Valuation Re-Rating Should Drive Upside

Danaher Appoints Martin Stumpe as Chief Technology and AI Officer

Jun 27, 2025, 7:35 AM EDT - 2 months ago

Danaher Appoints Martin Stumpe as Chief Technology and AI Officer

Danaher appoints Greg Milosevich to Executive Vice President, Life Sciences

Jun 27, 2025, 7:30 AM EDT - 2 months ago

Danaher appoints Greg Milosevich to Executive Vice President, Life Sciences

Danaher: High Capex And Low Debt Despite Trump Legislation

Jun 19, 2025, 12:33 PM EDT - 3 months ago

Danaher: High Capex And Low Debt Despite Trump Legislation

Danaher Schedules Second Quarter 2025 Earnings Conference Call

Jun 17, 2025, 4:30 PM EDT - 3 months ago

Danaher Schedules Second Quarter 2025 Earnings Conference Call

Prosperity Partners Completes Acquisition of Danaher Attig & Plante

Jun 4, 2025, 9:00 AM EDT - 3 months ago

Prosperity Partners Completes Acquisition of Danaher Attig & Plante

SCIEX Sets a New Standard in Accurate Mass Quantitation With the ZenoTOF 8600 System and New Software Collaborations

Jun 2, 2025, 7:00 AM EDT - 3 months ago

SCIEX Sets a New Standard in Accurate Mass Quantitation With the ZenoTOF 8600 System and New Software Collaborations

Software Launches for SCIEX OS Ecosystem to Help Scientists Accelerate Discoveries and Streamline Lab Operations

Jun 2, 2025, 7:00 AM EDT - 3 months ago

Software Launches for SCIEX OS Ecosystem to Help Scientists Accelerate Discoveries and Streamline Lab Operations

SCIEX and Evosep expand access to standardized proteomics for Pharma and Biotech with new reseller agreement

Jun 2, 2025, 7:00 AM EDT - 3 months ago

SCIEX and Evosep expand access to standardized proteomics for Pharma and Biotech with new reseller agreement

Danaher Announces Diagnostic Development and Commercialization Partnership to Scale Precision Medicine

May 29, 2025, 4:30 PM EDT - 3 months ago

Danaher Announces Diagnostic Development and Commercialization Partnership to Scale Precision Medicine

AZN

Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

May 28, 2025, 12:22 PM EDT - 4 months ago

Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

AMGN BIIB GILD IBB ILMN NVS SDGR

Danaher Corporation (DHR) BofA Securities 2025 Healthcare Conference (Transcript)

May 15, 2025, 3:32 PM EDT - 4 months ago

Danaher Corporation (DHR) BofA Securities 2025 Healthcare Conference (Transcript)

Danaher to Present at Bank of America Securities Healthcare Conference

May 7, 2025, 4:15 PM EDT - 4 months ago

Danaher to Present at Bank of America Securities Healthcare Conference

Danaher: A Capital Intensive Business Offering Low Risk, Low Reward Opportunity

May 6, 2025, 8:34 AM EDT - 4 months ago

Danaher: A Capital Intensive Business Offering Low Risk, Low Reward Opportunity

Danaher: Q1 Beat Fails To Trigger Guidance Upgrade

May 2, 2025, 4:00 AM EDT - 4 months ago

Danaher: Q1 Beat Fails To Trigger Guidance Upgrade

Baron Health Care Fund Q1 2025 Top Contributors And Detractors

Apr 29, 2025, 11:30 AM EDT - 5 months ago

Baron Health Care Fund Q1 2025 Top Contributors And Detractors

ACLX BSX GKOS INSM ISRG LLY RDNT

Kytopen and Aldevron Expedite Cell Therapy Manufacturing Through Their Collaborative CRISPR-mediated Cellular Engineering Workflow

Apr 29, 2025, 10:07 AM EDT - 5 months ago

Kytopen and Aldevron Expedite Cell Therapy Manufacturing Through Their Collaborative CRISPR-mediated Cellular Engineering Workflow

Danaher Corporation (DHR) Q1 2025 Earnings Call Transcript

Apr 22, 2025, 11:09 AM EDT - 5 months ago

Danaher Corporation (DHR) Q1 2025 Earnings Call Transcript

Danaher Beats Q1 Expectations, Signals Caution Ahead In 'Unusual Times'

Apr 22, 2025, 8:57 AM EDT - 5 months ago

Danaher Beats Q1 Expectations, Signals Caution Ahead In 'Unusual Times'

Danaher beats quarterly profit, expects incremental costs from US tariffs

Apr 22, 2025, 6:57 AM EDT - 5 months ago

Danaher beats quarterly profit, expects incremental costs from US tariffs

Danaher Reports First Quarter 2025 Results

Apr 22, 2025, 6:00 AM EDT - 5 months ago

Danaher Reports First Quarter 2025 Results

3 Wide-Moat Dividend Stars For A Championship Portfolio

Apr 2, 2025, 7:30 AM EDT - 6 months ago

3 Wide-Moat Dividend Stars For A Championship Portfolio

JNJ NEE

Danaher Corporation: A Mixed Bag Of Strength And Stagnation

Mar 31, 2025, 2:27 AM EDT - 6 months ago

Danaher Corporation: A Mixed Bag Of Strength And Stagnation

Danaher: Some Near-Term Headwinds, But Good Long-Term Prospects And Low Valuations

Mar 30, 2025, 11:19 PM EDT - 6 months ago

Danaher: Some Near-Term Headwinds, But Good Long-Term Prospects And Low Valuations

8 Upcoming Dividend Increases, Including A King

Mar 24, 2025, 5:06 PM EDT - 6 months ago

8 Upcoming Dividend Increases, Including A King

BBY CINF CSR DKS ELS KFY RNP

Danaher: Near 5-Year Low Is A Great Entry Point

Mar 22, 2025, 8:00 AM EDT - 6 months ago

Danaher: Near 5-Year Low Is A Great Entry Point

Danaher Schedules First Quarter 2025 Earnings Conference Call

Mar 20, 2025, 4:15 PM EDT - 6 months ago

Danaher Schedules First Quarter 2025 Earnings Conference Call

Beckman Coulter Announces FDA clearance of DxC 500i Clinical Analyzer, an integrated Clinical Chemistry and Immunoassay System

Mar 10, 2025, 8:30 AM EDT - 6 months ago

Beckman Coulter Announces FDA clearance of DxC 500i Clinical Analyzer, an integrated Clinical Chemistry and Immunoassay System

Danaher Corporation (DHR) TD Cowen 45th Annual Health Care Conference Transcript

Mar 5, 2025, 1:25 PM EST - 7 months ago

Danaher Corporation (DHR) TD Cowen 45th Annual Health Care Conference Transcript

Danaher to Present at TD Cowen Health Care Conference

Feb 25, 2025, 4:15 PM EST - 7 months ago

Danaher to Present at TD Cowen Health Care Conference

BillionerOfKing
BillionerOfKing Sep. 18 at 4:01 AM
$DHR Current Stock Price: $192.89 Contracts to trade: $190 DHR Sep 19 2025 Call Entry: $3.40 Exit: $4.67 ROI: 37% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 17 at 6:05 PM
Enter: $DHR OCT 10 2025 $195 CALLS Buy in Price: $3.98 - $5.00 Take Profit: $5.77 Stop Bleeding: $3.50 ROI Potential: 45% Exit Within: 201 Minutes https://moneygroup.us/alerts
0 · Reply
ZacksResearch
ZacksResearch Sep. 16 at 4:36 PM
$DHR struggles as Life Sciences segment faces headwinds 📉 Core revenues from DHR's Life Sciences segment declined 4% YoY in Q1 and fell 2.5% YoY in Q2, hurt by weak demand in academic and government markets. However, increased demand in microelectronics and aerospace end markets and new products like ZenoTOF 8600 are supporting growth. Meanwhile, shares are down 30.8% over the past year, with a high P/E ratio of 22.62X vs. the industry's 15.09X. See the full analysis here 👉 https://www.zacks.com/stock/news/2752326/danahers-life-sciences-segment-shrinks-whats-the-path-forward?cid=sm-stocktwits-2-2752326-body-12649&ADID=SYND_STOCKTWITS_TWEET_2_2752326_BODY_12649
0 · Reply
ZacksResearch
ZacksResearch Sep. 16 at 3:36 PM
$DHR Life Sciences is shrinking — what’s next? 🧬 Revenues are sliding on weak demand, but fresh products and biotech advances could open new growth paths. Full outlook here 👉 https://www.zacks.com/stock/news/2752326/danahers-life-sciences-segment-shrinks-whats-the-path-forward?cid=sm-stocktwits-2-2752326-teaser-12647&ADID=SYND_STOCKTWITS_TWEET_2_2752326_TEASER_12647
0 · Reply
HODLcoin
HODLcoin Sep. 16 at 2:17 PM
$DHR so bullish 🚀
0 · Reply
WSAnalysis
WSAnalysis Sep. 15 at 4:30 PM
$DHR this has to be one of the Best Buy’s in the market for upside. $ONTO isn’t far off. Sold $TSLA. Repositioning
0 · Reply
SilverEagle
SilverEagle Sep. 15 at 4:28 PM
$DHR gonna slip down to pre covid highs?
1 · Reply
StockAutoPro
StockAutoPro Sep. 15 at 2:08 PM
$DHR: Buy target $188.05 Sell target $199.55 Consider buying as recent acquisitions in life sciences sector could boost growth.
0 · Reply
StockAutoPro
StockAutoPro Sep. 14 at 3:09 PM
$DHR: Buy target $188.05 Sell target $199.55 Despite pandemic-related challenges, this DHR sector company shows strong growth potential due to its innovative product line.
0 · Reply
WSAnalysis
WSAnalysis Sep. 13 at 12:44 AM
$DHR time to buy
1 · Reply
HodlCommander
HodlCommander Sep. 12 at 5:47 PM
What role could $DHR play in the quantum‑biotech revolution? AlphaBriefing’s article points to Danaher’s imaging tools benefiting from quantum sensors. Full article: https://www.alphabriefing.com/quantum-sensors-inside-living-cells-the-next-frontier-for-brain-computer-interfaces/
0 · Reply
ZacksResearch
ZacksResearch Sep. 11 at 5:05 PM
$DHR Biotechnology segment: solid growth, but is it enough? 📈 🔬 Bioprocessing demand fueled a 6% increase in core revenues YoY in Q2, though discovery and medical businesses face headwinds amid equipment demand drop 📊 Trading at a forward P/E of 23.13X, above industry average Opportunity assessment here 👉 $CVS $LH https://www.zacks.com/stock/news/2750317/danahers-biotechnology-growth-picks-up-a-sign-of-more-upside?cid=sm-stocktwits-2-2750317-body-12073&ADID=SYND_STOCKTWITS_TWEET_2_2750317_BODY_12073
0 · Reply
ZacksResearch
ZacksResearch Sep. 11 at 4:05 PM
$DHR showing biotech strength — is more upside on deck? 📈 Biotechnology grew 6% in Q2, powered by bioprocessing, even as research equipment demand lagged. Full breakdown on $DHR’s growth drivers 👉 https://www.zacks.com/stock/news/2750317/danahers-biotechnology-growth-picks-up-a-sign-of-more-upside?cid=sm-stocktwits-2-2750317-teaser-12071&ADID=SYND_STOCKTWITS_TWEET_2_2750317_TEASER_12071
0 · Reply
newpragmatic
newpragmatic Sep. 10 at 3:12 PM
$DHR big buyback announced. I’m back in after selling in the 250s earlier this year. Will add at 190, 185, etc if we get there.
0 · Reply
SuperGreenToday
SuperGreenToday Sep. 10 at 3:38 AM
$DHR Its conglomerate premium is justified only by its best-in-class capital allocation and ability to consistently acquire and improve high-margin niche life science and diagnostic businesses.
0 · Reply
StockAutoPro
StockAutoPro Sep. 8 at 2:57 PM
$DHR: Buy target $193.13 Sell target $204.89 Strong earnings report indicates potential growth in the industrial technology sector. Consider buying.
0 · Reply
StockAutoPro
StockAutoPro Sep. 7 at 4:16 PM
$DHR: Buy target $198.21 Sell target $210.22 Expect potential growth in healthcare company due to promising pipeline of medical innovations.
0 · Reply
StockAutoPro
StockAutoPro Sep. 5 at 7:14 PM
$DHR: Buy target $198.22 Sell target $210.23 Strong quarterly earnings report suggests potential upside in this leading industrial technology company.
0 · Reply
StockAutoPro
StockAutoPro Sep. 4 at 4:19 AM
$DHR: Buy target $197.44 Sell target $209.41 Potential growth observed in medical technology firm due to pandemic-induced healthcare demand.
0 · Reply
StockAutoPro
StockAutoPro Sep. 3 at 2:06 PM
$DHR: Buy target $201.79 Sell target $213.98 Strong earnings growth forecast indicating potential upside for this leading medical diagnostics company.
0 · Reply
TechTraderGrok
TechTraderGrok Sep. 2 at 8:24 PM
Sold $DHR at $203.82 (+2.4%). From Grok: "Exit long on DHR as price has dipped below EMA in a weakening uptrend with no volume capitulation, recent failure to break resistance near 216, and momentum indicators like RSI at 48 showing loss of upside steam, targeting risk management ahead of potential further pullback to supports around 190-200 over the next few weeks." https://www.techtrader.ai/grokwall/?post=14691&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
ZacksResearch
ZacksResearch Sep. 2 at 4:49 PM
$DHR shows resilience with an impressive 7.2% gain in 3 months compared to the industry’s 3.8% growth! 📈 🔬 Bioprocessing orders up for 8 consecutive quarters 💊 Core revenues in the Biotechnology segment up 6% YoY 💡 Strategic acquisitions like Abcam boost Life Sciences by 1.5% Can DHR maintain its momentum? Full insights here 👉 https://www.zacks.com/stock/news/2746202/danaher-gains-from-business-strength-amid-persisting-headwinds?cid=sm-stocktwits-2-2746202-body-10538&ADID=SYND_STOCKTWITS_TWEET_2_2746202_BODY_10538
0 · Reply